Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
13 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
16 Aug 23
8-K
Changes in Registrant's Certifying Accountant
26 Jan 23
8-K
Entry into a Material Definitive Agreement
21 Jun 22
8-K
Entry into a Material Definitive Agreement
19 May 22
8-K/A
Changes in Registrant's Certifying Accountant
10 Nov 21
8-K
Termination of a Material Definitive Agreement
1 Nov 21
8-K
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric
19 Aug 21
8-K
Changes in Registrant's Certifying Accountant
4 Aug 21
8-K
Entry into a Material Definitive Agreement
16 Mar 21
8-K
Entry into a Material Definitive Agreement
28 May 20
Registration and prospectus
S-1/A
IPO registration (amended)
14 Jun 21
S-1
IPO registration
7 May 21
S-1/A
IPO registration (amended)
16 Jul 20
S-1
IPO registration
8 Jul 20
S-1/A
IPO registration (amended)
10 Feb 20
S-1
IPO registration
16 Jan 20
8-A12G
Registration of securities
14 Feb 19
POS AM
Prospectus update (post-effective amendment)
27 Jun 18
S-1/A
IPO registration (amended)
25 Aug 17
S-1/A
IPO registration (amended)
8 Aug 17
Other
EFFECT
Notice of effectiveness
29 Jun 21
CORRESP
Correspondence with SEC
24 Jun 21
CORRESP
Correspondence with SEC
14 Jun 21
UPLOAD
Letter from SEC
24 May 21
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
15 Jul 20
UPLOAD
Letter from SEC
14 Jul 20
EFFECT
Notice of effectiveness
13 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20